# CARMEN-LC04 (NCT04394624)

> Tusamitamab Ravtansine (SAR408701) in Combination With Ramucirumab or Ramucirumab and Pembrolizumab in Pretreated Patients With NSQ NSCLC (CARMEN-LC04)

No report yet. It can be ordered.

- Drugs tested: tusamitamab ravtansine plus ramucirumab; tusamitamab ravtansine plus ramucirumab plus pembrolizumab
- Indication: previously treated CEACAM5-positive metastatic non-squamous NSCLC

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT04394624
- Phase: PHASE2
- Status: TERMINATED
- Sponsor: Sanofi
- Conditions: Non-small Cell Lung Cancer Metastatic
- Interventions: SAR408701; ramucirumab; pembrolizumab
- Enrollment: 31
- Primary outcome: Doublet Cohort - Part 1: Number of Participants With Study Drug-Related Dose-Limiting Toxicity (DLT)
- Primary outcome: Doublet Cohort - Part 2: Objective Response Rate (ORR)
- Primary outcome: Triplet Cohort: Number of Participants With Study Drug-Related Dose-Limiting Toxicity

## Indexed commentary on CARMEN-LC04 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 3

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=carmen-lc04-nct04394624